Daiwa Securities Group Inc. Grows Position in Humana Inc. (NYSE:HUM)

Daiwa Securities Group Inc. grew its stake in shares of Humana Inc. (NYSE:HUM) by 8.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,154 shares of the insurance provider’s stock after purchasing an additional 1,022 shares during the period. Daiwa Securities Group Inc.’s holdings in Humana were worth $4,915,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Intech Investment Management LLC boosted its holdings in Humana by 46.2% during the fourth quarter. Intech Investment Management LLC now owns 42,287 shares of the insurance provider’s stock worth $19,359,000 after buying an additional 13,356 shares in the last quarter. AdvisorShares Investments LLC purchased a new stake in shares of Humana during the 4th quarter worth approximately $421,000. Sei Investments Co. boosted its stake in shares of Humana by 0.4% during the 1st quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock worth $21,462,000 after acquiring an additional 264 shares in the last quarter. Cetera Advisors LLC grew its holdings in shares of Humana by 472.1% in the 1st quarter. Cetera Advisors LLC now owns 10,098 shares of the insurance provider’s stock worth $3,501,000 after acquiring an additional 8,333 shares during the period. Finally, Cetera Investment Advisers increased its stake in Humana by 249.0% in the 1st quarter. Cetera Investment Advisers now owns 20,945 shares of the insurance provider’s stock valued at $7,262,000 after purchasing an additional 14,944 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

Shares of Humana stock opened at $324.50 on Friday. The stock has a market capitalization of $39.10 billion, a P/E ratio of 20.21, a PEG ratio of 2.80 and a beta of 0.50. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The business’s fifty day moving average price is $365.05 and its 200 day moving average price is $347.04. Humana Inc. has a twelve month low of $298.61 and a twelve month high of $530.54.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating the consensus estimate of $5.89 by $1.07. The business had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company’s revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company posted $8.94 EPS. As a group, research analysts anticipate that Humana Inc. will post 16 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.09%. The ex-dividend date is Monday, September 30th. Humana’s dividend payout ratio is presently 22.04%.

Wall Street Analyst Weigh In

HUM has been the topic of several research reports. Truist Financial upped their target price on Humana from $355.00 to $400.00 and gave the company a “hold” rating in a report on Monday, July 15th. Morgan Stanley started coverage on shares of Humana in a research note on Monday, June 24th. They issued an “equal weight” rating and a $374.00 price objective on the stock. TD Cowen lifted their target price on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Piper Sandler assumed coverage on shares of Humana in a research report on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price target on the stock. Finally, Oppenheimer lifted their price objective on Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Thirteen analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $398.70.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.